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Abstract
Background Antidepressants are commonly prescribed for depression, but it is unclear whether treatment efficacy depends 
on severity and duration of symptoms and how prescribing might be targeted cost-effectively.
Objectives We investigated the cost-effectiveness of the antidepressant sertraline compared with placebo in subgroups 
defined by severity and duration of depressive symptoms.
Methods We undertook a cost-effectiveness analysis from the perspective of the NHS and Personal and Social Services 
(PSS) in the UK alongside the PANDA (What are the indications for Prescribing ANtiDepressants that will leAd to a clini-
cal benefit?) randomised controlled trial (RCT), which compared sertraline with placebo over a 12-week period. Quality 
of life data were collected at baseline and at 2, 6, and 12 weeks post-randomisation using EQ-5D-5L, from which we cal-
culated quality-adjusted life years (QALYs). Costs (in 2017/18£) were collected using patient records and from resource 
use questionnaires administered at each follow-up interval. Differences in mean costs and mean QALYs and net monetary 
benefits were estimated. Our primary analysis used net monetary benefit regressions to identify any interaction between 
the cost-effectiveness of sertraline and subgroups defined by baseline symptom severity (0–11; 12–19; 20+ on the Clinical 
Interview Schedule—Revised) and, separately, duration of symptoms (greater or less than 2 years duration). A secondary 
analysis estimated the cost-effectiveness of sertraline versus placebo, irrespective of duration or severity.
Results There was no evidence of an association between the baseline severity of depressive symptoms and the cost-effec-
tiveness of sertraline. Compared to patients with low symptom severity, the expected net benefits in patients with moderate 
symptoms were £24 (95% CI − £280 to £328; p value 0.876) and the expected net benefits in patients with high symptom 
severity were £37 (95% CI − £221 to £296; p value 0.776). Patients who had a longer history of depressive symptoms at 
baseline had lower expected net benefits from sertraline than those with a shorter history; however, the difference was 
uncertain (− £27 [95% CI − £258 to £204]; p value 0.817). In the secondary analysis, patients treated with sertraline had 
higher expected net benefits (£122 [95% CI £18 to £226]; p value 0.101) than those in the placebo group. Sertraline had a 
high probability (> 95%) of being cost-effective if the health system was willing to pay at least £20,000 per QALY gained.
Conclusions We found insufficient evidence of a prespecified threshold based on severity or symptom duration that GPs 
could use to target prescribing to a subgroup of patients where sertraline is most cost-effective. Sertraline is probably a cost-
effective treatment for depressive symptoms in UK primary care.
Trial Registration Controlled Trials ISRCTN Registry, ISRCTN84544741.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-019-00188 -5) contains 
supplementary material, which is available to authorized users.
 * William Hollingworth 
 william.hollingworth@bristol.ac.uk
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1 Introduction
Depression is the leading cause of disability worldwide [1], 
affecting 4.4% of the world’s population, or 322 million peo-
ple [2]. Between 2005 and 2015, the number of people living 
with depression increased by 18.4% [1]. First-line pharma-
cological treatment of depression is usually with selective 
serotonin reuptake inhibitor (SSRI) antidepressants, which 
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Key Points for Decision Makers 
Sertraline is often prescribed by GPs for symptoms of 
depression, but it is unclear which patients benefit most.
We found insufficient evidence that either symptom 
severity or duration could be used by GPs to better target 
the prescribing of sertraline.
Sertraline is probably a cost-effective treatment for 
depressive symptoms in UK primary care.
the influence of severity and duration of depressive symp-
toms on response to sertraline compared with placebo in 
people presenting to primary care with depression. The 
results of the RCT are detailed in Lewis et al. [16]. In this 
paper, we estimated the cost-effectiveness of sertraline in 
comparison with placebo at the end of 12 weeks of follow-up 
in relation to the baseline severity and duration of depres-
sive symptoms. A secondary analysis estimated the cost-
effectiveness of sertraline in comparison with placebo in all 
patients, irrespective of severity or duration.
2  Methods
The published trial protocol provides full details of eligi-
bility criteria, recruitment, randomisation, treatment regi-
mens and assessment methods [17]. In brief, PANDA is a 
randomised, double-blind, placebo-controlled trial in which 
participants are individually randomised to sertraline or pla-
cebo. Eligible participants aged between 18 and 74 were 
identified in primary care with depression or low mood dur-
ing the past 2 years and had not received antidepressant or 
anti-anxiety medication in the previous 8 weeks. Trial par-
ticipants were recruited from 179 primary care surgeries in 
four UK sites. Participants were randomised to receive either 
sertraline or matching placebo, starting at 50 mg daily for 
1 week, increasing to 100 mg daily for up to 11 weeks (with 
the option of increasing to 150 mg if required). Sertraline 
is a cheap off-patent medication (approximately £0.80–1.00 
per 28 tablets) [18]. The primary outcome was depressive 
symptoms measured by the Patient Health Questionnaire 9 
(PHQ-9) at 6 weeks postrandomisation. The clinical effec-
tiveness findings of the PANDA trial have been reported in 
detail [16], and are briefly summarised here in the “Results” 
section.
The primary economic analysis took an NHS and per-
sonal social services (PSS) perspective. A secondary anal-
ysis was undertaken from the perspective of individual 
patients, accounting for costs such as expenditure on private 
health care. We also considered the cost to society of work 
absences. The time horizon for the economic analysis was 
up to 12 weeks post-randomisation, reflecting the duration 
of follow-up in the trial. As the follow-up period does not 
extend beyond one year, discounting of costs and benefits 
was not applied. The analysis plan was agreed with the trial 
steering committee and was deposited in UCL Discovery 
[19].
2.1  Estimating Benefits
The primary economic outcome measure was quality-
adjusted life years (QALYs) derived from utility scores, 
obtained using the EQ-5D-5L quality of life instrument [20]. 
provide small beneficial effects over placebo [3]. Use of 
antidepressants has increased dramatically in recent years, 
particularly in high-income countries. In 2016, 65 million 
antidepressant items were prescribed in England, more than 
double the number prescribed ten years earlier (31 million) 
[4]. The associated healthcare costs of increased use of 
antidepressants are considerable, despite the introduction 
of cheaper generic SSRI equivalents. In 2016, primary care 
prescriptions of antidepressants in England cost the National 
Health Service (NHS) £266.6 million [4].
Depression is typically managed by general practitioners 
(GPs), with the exception of a small proportion of cases that 
require specialist mental or social care services [5]. Manage-
ment options include active monitoring, low-intensity psy-
chosocial interventions, group cognitive behavioural therapy 
and drug treatment [6]. The decision to prescribe is gener-
ally based on clinical judgement of patients’ symptoms and 
not on the results of standardised scales or questionnaires. 
Patients may be considered mildly, moderately or severely 
depressed, depending on their associated symptoms [5, 7]; 
however, it is unclear which patient groups are most likely 
to benefit from treatment with SSRIs. Patients with mild 
depressive symptoms are commonly prescribed antidepres-
sants despite not meeting International Classification of Dis-
eases (ICD-10) criteria for depression [5, 8], and there is 
limited evidence to support the use of antidepressants in this 
population [9]. It has been proposed that patients with more 
severe symptoms may benefit more from antidepressants, 
although the evidence is not clear-cut [10–14]. Patients with 
dysthymia—depression that is present for two or more years 
but does not meet diagnostic criteria [15]—might also ben-
efit more from antidepressants. Previous studies were not 
designed to explore the cost-effectiveness of antidepressants 
by severity and duration of depression.
We undertook a large pragmatic randomised controlled 
trial (the PANDA RCT—What are the indications for Pre-
scribing ANtiDepressants that will leAd to a clinical ben-
efit?) to investigate the clinical effectiveness of a commonly 
prescribed SSRI, sertraline, versus placebo, and to explore 
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EQ-5D-5L questionnaires were completed by participants 
prior to randomisation (baseline) and at 2, 6 and 12 weeks 
post-randomisation. Baseline and research follow-up assess-
ments took place at the participant’s home, general practice, 
or at university premises. Utility scores were derived from 
responses to the EQ-5D-5L using valuations obtained from 
an English population [21]. We used linear interpolation of 
responses at baseline and at 2, 6 and 12 weeks to estimate 
QALYs over the 12-week period, adjusting for baseline EQ-
5D-5L scores in regression analyses as recommended in the 
literature [22].
2.2  Estimating Costs
For the primary analysis, data were collected on health ser-
vice use, including primary care consultations, sertraline, 
other prescribed medication, hospital admission, outpatient 
attendance, emergency department attendance and commu-
nity-based care. For secondary analyses, we also included 
productivity losses due to mental health problems and per-
sonal costs (e.g. payments for additional care). Primary care 
consultations were captured through electronic downloads 
of GP records. Manual data extraction was used as a backup 
if GP records did not support automatic downloads. NHS 
secondary care, community care, care from social services, 
time off work and patient personal resource use during trial 
follow-up was captured using patient-reported question-
naires completed at 2, 6 and 12 weeks.
The cost of medications was estimated from the British 
National Formulary [23]. Community and primary care costs 
were based on national estimates [24]. Codes for Healthcare 
Resource Groups (groups of events that have been judged 
to consume similar levels of resources) were assigned to 
secondary care contacts and were costed based on aggre-
gate national reference costs where available (for example, 
ultrasound) [25]. Productivity costs were estimated based on 
national average weekly earnings stratified by sex [26]. All 
costs are reported for the financial year 2017/18 in pounds 
sterling (£) and adjusted for inflation using the Hospital and 
Community Health Services Index where necessary [24].
2.3  Cost‑Effectiveness Analysis
A cost-effectiveness analysis was conducted using the 
intention-to-treat principle, comparing the two groups as 
randomised and including all patients in the analysis. This 
analysis estimated the cost-effectiveness of sertraline and 
how the net monetary benefit (NMB) of sertraline varies 
with baseline severity of depression and with symptom dura-
tion. NMB is a summary statistic used to present cost-effec-
tiveness results. It estimates the value of an intervention in 
monetary terms using a predefined willingness to pay thresh-
old for a unit of benefit, typically QALY. An intervention is 
said to be cost-effective if the NMB is positive. The NMB 
is recommended for use in identifying heterogeneity in cost-
effectiveness between subgroups as, unlike the incremen-
tal cost-effectiveness ratio (ICER) that was specified in the 
trial protocol, the NMB is a linear combination of individual 
patient costs and QALYs that facilitates regression analysis 
using subgroup interaction terms [27].
Data cleaning was undertaken prior to the unblinding of 
the economic researcher to the study groups. This involved 
the correction of obvious ‘free text’ response errors (e.g. mis-
spelt drug names) and group coding of similar resource items 
to enable unit costing. Multiple imputation was subsequently 
undertaken for missing data. The primary analysis was based 
on imputed datasets and included all participants [28, 29]. 
We implemented multiple imputation by chained equations 
on data that were assumed missing at random. The imputa-
tion model was stratified by trial arm and included complete 
demographic data (e.g. age, ethnicity, financial stability, mar-
ital status) alongside clinical outcome variables (on sever-
ity and duration of depressive symptoms) at baseline, utility 
score at baseline, cost and utility variables with missing data, 
and site practice (i.e. London, Bristol, Liverpool, York). We 
imputed costs at the aggregate level (e.g. total NHS and PSS 
costs). We imputed utility data for each follow-up period 
and used these to generate QALY estimates. The number of 
imputations (n = 40) was selected to be greater than the pro-
portion of missing data, as per White et al. [30]. A complete 
case analysis was also undertaken for comparative purposes.
We estimated the incremental difference in mean total 
costs and mean QALYs between the two arms of the trial 
and 95% confidence intervals using ordinary least squares 
regression. In the primary analysis, cost and QALY data were 
combined to calculate a NMB statistic [31] from the NHS 
and PSS perspective. For each individual i, the NMB statistic 
is  NMBi = λEi − Ci, where Ci is the cost of care for that indi-
vidual, Ei is the QALYs of that individual, and λ is the cost-
effectiveness threshold (i.e. the amount society is willing to 
pay for a QALY). In all analyses, we used the commonly used 
NICE threshold values of £20,000 and £30,000 per QALY. 
We estimated NMB regressions using interactions between 
the treatment indicator and baseline severity (model 1) and in 
a separate model between the treatment indicator and symp-
tom duration (model 2) to explore whether sertraline was 
differentially more cost-effective across subgroups defined 
by symptom severity or duration. Three severity strata (0–11; 
12–19; 20+ on the Clinical Interview Schedule—Revised 
(CIS-R) at baseline) [32] and two duration strata (less than 
2 years or 2 years or more) were prespecified in the trial pro-
tocol [17]. The CIS-R is a widely used diagnostic assessment 
tool for mental health conditions. The CIS-R score indicates 
the severity of psychological symptoms. A positive regres-
sion coefficient on the interaction term between the treat-
ment group and patient subgroup indicates that sertraline is 
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potentially more cost-effective in that subgroup compared 
with the reference subgroup.
In a prespecified secondary analysis, we estimated the cost-
effectiveness of sertraline versus placebo (model 3), irrespec-
tive of baseline severity and symptom duration. All regression 
models adjusted for baseline utility scores and study centre as 
a random effect. Uncertainty in the point estimates of NMB 
was quantified using 95% confidence intervals estimated from 
the regressions. We calculated cost-effectiveness acceptability 
curves (CEACs) [33] to probe the uncertainty in the optimal 
treatment for various different cost-effectiveness thresholds.
In a post-hoc sensitivity analysis, we examined the impact 
of excluding secondary care and prescriptions extracted from 
medical records that were judged to be not clearly related to 
the treatment of depression (Supplementary Table 1 in the 
Electronic supplementary material, ESM). We also conducted 
a further sensitivity analysis in which we removed all second-
ary care costs from total NHS and PSS costs. This assessed 
whether our findings were robust to infrequent but expensive 
hospitalisations that might differ between arms by chance.
The economic evaluation followed best practice guide-
lines, as outlined by Husereau et al. [34] and detailed in 
Supplementary Table 2 in the ESM. Stata software (version 
15) [35] was used for all analyses.
3  Results
3.1  Patient Characteristics and Trial Outcomes
We randomised 655 patients, 326 to sertraline and 329 to 
placebo. Two patients were missing substantial proportions 
of the baseline assessment and were excluded, leaving 653 
for analyses. 505 (77.3%) patients had complete EQ-5D-5L 
responses at all four assessment points. A smaller propor-
tion (381/653; 58.3%) had complete resource use data avail-
able from primary care notes and self-reported assessments. 
Follow-up rates were similar in both arms at all time points 
(Supplementary Fig. 1 in the ESM). At recruitment, the 
mean age was 39.7 years (SD 14.96), 59% (n = 384) were 
female, and the mean PHQ-9 score was 12.0 (SD 5.8) [16]. 
Table 1 provides details of baseline PHQ-9 scores and EQ-
5D-5L scores across the subgroups defined by severity and 
duration. At baseline, patients with severe or prolonged 
depressive symptoms (≥ 2 years) had worse EQ-5D-5L and 
PHQ-9 scores. As previously reported, there was a 5% rela-
tive reduction (adjusted proportional change 0.95 [95% CI 
0.85–1.07]) in PHQ-9 depressive symptom scores in the 
sertraline group at 6 weeks, but the confidence interval did 
not exclude the possibility of no treatment effect [16]. There 
was stronger evidence for a treatment effect of sertraline 
on PHQ-9 score at 12 weeks (adjusted proportional change 
0.87 [95% CI 0.79–0.97]) [16]. In the sections below, we 
first report the cost-effectiveness of sertraline versus placebo 
(secondary analysis) and then explore whether sertraline was 
differentially more cost-effective across subgroups defined 
by symptom severity or duration (primary analyses).
3.2  Cost‑Effectiveness (Sertraline Versus Placebo)
In the imputed dataset, total NHS and PSS costs were lower 
in the sertraline group (£154) than in the placebo group 
(£177), but the difference was small and there was no evi-
dence of a treatment effect on costs (difference − £22 [95% 
Table 1  Baseline health-related 
quality of life in subgroups 
defined by depressive symptom 
severity and duration
Sertraline (n = 324) Placebo (n = 329) Overall (n = 653)
Mean (SE) Mean (SE) Mean (SE)
Severity subgroups
 EQ5D-5L
  Mild (n = 129) 0.816 (0.014) 0.796 (0.017) 0.806 (0.011)
  Moderate (n = 173) 0.769 (0.016) 0.800 (0.012) 0.785 (0.010)
  Severe (n = 349) 0.652 (0.016) 0.653 (0.016) 0.653 (0.011)
 PHQ-9
  Mild (n = 128) 5.657 (0.410) 6.049 (0.548) 5.844 (0.337)
  Moderate (n = 173) 9.500 (0.432) 10.258 (0.420) 9.890 (0.302)
  Severe (n = 350) 15.308 (0.370) 15.275 (0.349) 15.291 (0.254)
Duration subgroups
 EQ5D-5L
  < 2 years (n = 439) 0.729 (0.012) 0.743 (0.012) 0.736 (0.009)
  ≥ 2 years (n = 212) 0.690 (0.020) 0.673 (0.020) 0.681 (0.014)
 PHQ-9
  < 2 years (n = 438) 11.408 (0.400) 11.550 (0.388) 11.479 (0.278)
  ≥ 2 years (n = 213) 12.600 (0.567) 13.519 (0.521) 13.066 (0.385)
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CI − £87 to £42]; p value 0.490) (Table 2). Sensitivity anal-
yses excluding secondary care costs and costs not clearly 
associated with mental health care supported this finding, as 
did the complete case analysis. There was little difference in 
patient costs or time off work costs (i.e. productivity losses) 
between groups. The cost of sertraline in the intervention 
group over the 12 weeks of the trial was minimal. There 
were no large or consistent differences in the cost of other 
medications, primary care consultations, community-based 
care or hospital care between the sertraline or placebo 
groups during the 12-week follow-up.
Over the 12-week period, QALYs were marginally higher 
in the sertraline group (0.182) than the placebo group 
(0.177), but there was no strong evidence of a treatment 
effect using the imputed dataset (QALY difference 0.005 
[95% CI − 0.003 to 0.012]; p value 0.150) (Table 3). How-
ever, preference-based quality of life scores measured by the 
EQ-5D-5L increased (i.e. improved) in both groups from 
Table 2  Summary costs
CI confidence interval, NHS National Health Service, PSS Personal and Social Services, SD standard deviation, SE standard error
a Primary, secondary, and community-based care
b Mental-health-related medication and community care costs
c Standard errors reported here are due to imputed datasets
Sertraline (n = 324) Placebo (n = 329) Mean difference (n = 653)
Mean (SE)c Mean (SE)c Mean (95% CI) p value
Imputed
 Total NHS  costsa £154.01 (£18.97) £176.5 (£25.71) £− 22.48 (− £86.61 to £41.64) 0.490
 Total NHS mental-health-related  costsb £35.26 (£7.96) £55.12 (£12.11) £− 19.86 (− £49.16 to £9.44) 0.182
 Total NHS costs, excluding secondary care £98.39 (£14.92) £121.43 (£15.58) £− 23.04 (− £65.19 to £19.12) 0.283
 Total productivity losses £134.38 (£32.27) £120.58 (£25.93) £13.8 (− £68.03 to £95.63) 0.740
 Total patient costs £4.73 (£2.55) £7.93 (£2.68) £− 3.2 (− £10.46 to £4.06) 0.386
Sertraline (n = 174) Placebo (n = 207) Mean difference (n = 381)
Mean (SD) Mean (SD) Mean (95% CI) p value
Complete cases
 Total NHS  costsa £169.34 (£351.17) £188.42 (£423.05) − £19.08 (− £98.33 to £60.16) 0.636
 Total NHS mental-health-related  costsb £28.98 (£93.65) £50.92 (£167.33) − £21.94 (− £49.98 to £6.1) 0.125
 Total NHS costs, excluding secondary care £112.18 (£303.14) £124.36 (£274.77) − £12.18 (− £70.44 to £46.07) 0.681
 Total productivity losses £118.22 (£484.05) £69.61 (£246.46) £48.6 (− £27.05 to £124.26) 0.207
 Total patient costs £5.41 (£41.52) £10.83 (£47.24) − £5.42 (− £14.46 to £3.62) 0.239
Disaggregated costs (complete cases)
 Sertraline £3.81 (£0.62) £0 (£0) £3.81 (£3.72 to £3.89) 0.000
 Primary care consultations
  GP consultations £26.16 (£44.48) £27.53 (£39.55) − £1.37 (− £9.84 to £7.1) 0.750
  Nurse consultations £3.93 (£13) £5.14 (£11.3) − £1.21 (− £3.66 to £1.24) 0.332
  GP telephone calls £3.23 (£8.55) £2.72 (£8.69) £0.52 (− £1.23 to £2.26) 0.562
  Nurse telephone calls £0.5 (£2.43) £0.65 (£3.28) − £0.15 (− £0.74 to £0.44) 0.620
 Medications
  All £49.61 (£272.99) £37.64 (£215.99) £11.97 (− £37.31 to £61.25) 0.633
  Mental health £0.23 (£1.46) £0.23 (£2.2) £0 (− £0.39 to £0.38) 0.995
 Secondary care
  Inpatient care £3.55 (£46.78) £20.71 (£258.4) − £17.16 (− £56.21 to £21.89) 0.388
  Outpatient care £35.83 (£93.22) £33.39 (£102.76) £2.44 (− £17.49 to £22.36) 0.810
  Accident and emergency £17.78 (£85.67) £9.97 (£42.4) £7.82 (− £5.48 to £21.12) 0.249
 Community-based care
  Community care £23.6 (£90.59) £47.99 (£164.74) − £24.39 (− £51.9 to £3.11) 0.082
  Home visits £1.33 (£14.68) £2.45 (£30.18) − £1.12 (− £6.05 to £3.81) 0.655
  Additional help £0.02 (£0.23) £0.25 (£2.88) − £0.23 (− £0.66 to £0.2) 0.296
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baseline to 12 weeks. There was some evidence that ser-
traline was more cost-effective than placebo at a threshold 
of £20,000 (incremental NMB £122 [95% CI £18 to £226]; 
p value 0.022) and £30,000 (incremental NMB £171 [95% 
CI £33 to £310]; p value 0.016) per QALY, respectively 
(Table 4, model 3); sertraline had a high probability (> 95%) 
of being cost-effective if the health system is willing to pay 
more than £20,000 per QALY gained (Fig. 1).
3.3  Cost‑Effectiveness (in Subgroups Defined 
by Symptom Severity and Duration)
Participants with higher symptom severity reported lower 
utility scores during trial follow-up (Table 5), although sev-
eral patients reported high QALY scores despite high base-
line symptom severity (Supplementary Fig. 2 in the ESM). 
QALYs were slightly higher in the sertraline group in all 
three depressive symptom severity strata, but in each case 
Table 3  Utility scores and QALYs
CI confidence interval, QALYs quality-adjusted life years, SD standard deviation, SE standard error
Sertraline (n = 324) Placebo (n = 329) Mean difference (n = 653)
Mean (SE) Mean (SE) Mean (95% CI) p value
Imputed
 QALYs 0.182 (0.002) 0.177 (0.002) 0.005 (− 0.003 to 0.012) 0.150
Sertraline (n = 248) Placebo (n = 257) Mean difference (n = 505)
Mean (SD) Mean (SD) Mean (95% CI) p value
Complete cases
 Baseline 0.732 (0.172) 0.725 (0.188) 0.008 (− 0.024 to 0.039) 0.638
 2 weeks 0.774 (0.164) 0.756 (0.176) 0.018 (− 0.012 to 0.048) 0.236
 6 weeks 0.807 (0.180) 0.776 (0.185) 0.031 (− 0.001 to 0.063) 0.054
 12 weeks 0.815 (0.184) 0.790 (0.185) 0.025 (− 0.007 to 0.057) 0.128
 QALYs 0.183 (0.034) 0.178 (0.037) 0.006 (− 0.002 to 0.013) 0.078
Table 4  Incremental net monetary benefit results (imputed)
Model 1: interaction model between sertraline and baseline severity, adjusted for severity, duration, baseline utility and site practice
Model 2: interaction model between sertraline and duration, adjusted for duration, severity, baseline utility and site practice
Model 3: non-interaction model comparing sertraline vs placebo, adjusted for baseline utility and site practice
CI confidence interval, INMB incremental net monetary benefit
£20,000 WTP £30,000 WTP
INMB (95% CI) p value INMB (95% CI) p value
Model 1 (n = 650)
 Sertraline £91.94 (− £123.17 to £307.06) 0.401 £129.23 (− £150.48 to £408.94) 0.364
 Severity
  Low Reference Reference
  Moderate − £33.55 (− £275.23 to £208.13) 0.785 − £56.28 (− £354.6 to £242.04) 0.711
  High − £58.02 (− £337.46 to £221.42) 0.683 − £95.19 (− £457.35 to £266.98) 0.605
 Sertraline × severity
  Low Reference Reference
  Moderate £24.18 (− £279.96 to £328.31) 0.876 £47.23 (− £341.78 to £436.24) 0.811
  High £37.44 (− £221.35 to £296.24) 0.776 £44.46 (− £304.27 to £393.19) 0.802
Model 2 (n = 650)
 Sertraline £127.41 (− £2.25 to £257.08) 0.054 £177.96 (£9.14 to £346.78) 0.039
 Duration (> 2 years) £26.61 (− £125.95 to £179.18) 0.732 £10.71 (− £196.18 to £217.61) 0.919
 Sertraline × duration (> 2 years) − £27.14 (− £258.13 to £203.86) 0.817 − £37.39 (− £360.59 to £285.81) 0.820
Model 3 (n = 653)
 Sertraline vs placebo £121.83 (£17.79 to £225.87) 0.022 £171.12 (£32.68 to £309.55) 0.016
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the confidence interval included zero (Table 5). There were 
no consistent differences in the incremental costs of sertra-
line across all three symptom strata, and confidence intervals 
were wide (Table 5).
There was no evidence of an association between the 
baseline severity of depressive symptoms and the cost-
effectiveness of sertraline (Table 4, model 1). Compared 
to patients with low symptom severity at baseline, patients 
with moderate symptoms (difference in incremental NMB 
£24 [95% CI − £280 to £328]; p value 0.876) and patients 
with high symptom severity had higher incremental net ben-
efits of sertraline (difference in incremental NMB £37 [95% 
CI − £221 to £296]; p value 0.776). Similar findings were 
observed at the £30,000 per QALY threshold. Sertraline was 
probably (p > 0.7) cost-effective in all three severity sub-
groups at the £20,000 per QALY threshold (Fig. 2).
There was little obvious association between symptom 
duration and QALYs or costs (Supplementary Fig. 2 in the 
ESM). QALYs were slightly higher in the sertraline group in 
both strata of symptom duration, but the confidence intervals 
approached zero (Table 6). The NHS costs were lower in the 
sertraline group in both strata, but the confidence intervals 
were wide and included zero (Table 6). Patients who had a 
longer history of depressive symptoms at baseline (Table 4, 
model 2) had lower incremental net benefits from sertraline 
than those with a shorter history; however, the confidence 
Fig. 1  Cost effectiveness acceptability curve of sertraline versus pla-
cebo (imputed)
Table 5  Costs and outcomes in subgroups defined by depressive symptom severity (complete cases except where stated)
a At £20,000 per QALY threshold
Sertraline Placebo Difference
Mean (SD) Mean (SD) Mean (95% CI)
Mild (n = 103)
 Baseline utility score 0.815 (0.121) 0.806 (0.121) 0.009 (− 0.038 to 0.057)
 2 weeks utility score 0.842 (0.112) 0.825 (0.139) 0.016 (− 0.032 to 0.067)
 6 weeks utility score 0.874 (0.138) 0.843 (0.131)  0.030 (− 0.022 to 0.083)
 12 weeks utility score 0.893 (0.123) 0.860 (0.133) 0.033 (− 0.017 to 0.083)
QALYs (imputed, n = 129) 0.199 (0.003 SE) 0.192 (0.004 SE) 0.004 (− 0.004 to 0.012)
Total NHS costs (imputed, n = 129) £163.22 (£36.46 SE) £188.65 (£58.71 SE) − £18.92 (− £154.15 to £116.31)
Incremental  NMBa (imputed, n = 129) £101.83 (− £113.68 to £317.34)
Moderate (n = 137)
 Baseline utility score 0.776 (0.134) 0.792 (0.117) − 0.017 (− 0.059 to 0.026)
 2 weeks utility score 0.814 (0.163) 0.808 (0.101) 0.006 (− 0.040 to 0.052)
 6 weeks utility score 0.835 (0.183) 0.828 (0.132) 0.007 (− 0.046 to 0.061)
 12 weeks utility score 0.861 (0.163) 0.810 (0.157) 0.051 (− 0.003 to 0.105)
QALYs (imputed, n = 173) 0.191 (0.004 SE) 0.189 (0.003 SE) 0.007 (0 to 0.014)
Total NHS costs (imputed, n = 173) £175.5 (£50.35 SE) £160.03 (£56.17 SE) £3.65 (− £145.04 to £152.35)
Incremental  NMBa (imputed, n = 173) £134.56 (− £69.39 to £338.51)
Severe (n = 265)
 Baseline utility score 0.676 (0.187) 0.660 (0.213) 0.016 (− 0.032 to 0.065)
 2 weeks utility score 0.726 (0.168) 0.704 (0.202) 0.022 (− 0.023 to 0.067)
 6 weeks utility score 0.766 (0.183) 0.724 (0.209) 0.041 (− 0.006 to 0.089)
 12 weeks utility score 0.760 (0.198) 0.754 (0.206) 0.006 (− 0.043 to 0.055)
QALYs (imputed, n = 351) 0.171 (0.003 SE) 0.166 (0.003 SE) 0.005 (− 0.002 to 0.011)
Total NHS costs (imputed, n = 351) £140.02 (£18.59 SE) £180.5 (£28.41 SE) − £40.7 (− £108.63 to £27.24)
Incremental  NMBa (imputed, n = 351) £131.18 (− £18.49 to £280.86)
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intervals were wide (difference in incremental net benefit 
− £27 [95% CI − £258 to £204] at the £20,000 per QALY 
threshold; p value 0.817). The probability that sertraline 
is cost-effective in those with longer symptom duration 
exceeds 0.8 (Fig. 3).
3.4  Sensitivity Analyses
Restricting the analysis to patients with complete data did 
not change the conclusions (Supplementary Table 3 in the 
ESM). The results remained unchanged in sensitivity anal-
yses in which secondary care costs and costs not clearly 
associated with mental health care were excluded (Supple-
mentary Tables 4 and 5 in the ESM).
4  Discussion
4.1  Key Findings
We found insufficient evidence that variation in the cost-
effectiveness of sertraline according to severity or symptom 
duration at prespecified thresholds could be used by GPs 
to target prescribing to subgroups of patients. There was 
no evidence of a substantial treatment effect of sertraline 
on quality of life as measured by the EQ-5D-5L. However, 
sertraline is a cheap intervention that had a high probability 
of being cost-effective compared with placebo, on average, 
across primary care patients with depression or low mood.
4.2  Strengths and Weaknesses
The PANDA trial is a large publicly funded, placebo-con-
trolled trial of an antidepressant. We used pragmatic eli-
gibility criteria to recruit participants where the GP was 
uncertain about the benefit of an SSRI, which resulted in 
randomised patients ranging from those with very few to 
those with severe depressive symptoms. The wide spectrum 
of symptom severity and duration increased the likelihood 
of identifying subgroups where sertraline was more cost-
effective. The PANDA trial had a relatively short follow-up 
period and found no strong evidence that sertraline reduced 
depressive symptoms measured by the primary outcome 
Fig. 2  Cost-effectiveness acceptability curves of sertraline versus 
placebo in patients with different levels of severity of depression 
(imputed)
Table 6  Costs and outcomes in subgroups defined by symptom duration (complete cases except where stated)
Sertraline Placebo Difference
Mean (SD) Mean (SD) Mean (95% CI)
< 2 years (n = 342)
 Baseline utility score 0.732 (0.182) 0.734 (0.182) − 0.003 (− 0.041 to 0.036)
 2 weeks utility score 0.774 (0.176) 0.764 (0.170) 0.011 (− 0.026 to 0.048)
 6 weeks utility score 0.813 (0.194) 0.782 (0.191) 0.031 (− 0.010 to 0.072)
 12 weeks utility score 0.837 (0.170) 0.808 (0.181) 0.029 (− 0.008 to 0.067)
QALYs (imputed, n = 439) 0.185 (0.003 SE) 0.181 (0.002 SE) 0.006 (0.001 to 0.01)
Total NHS costs (imputed, n = 439) £168.6 (£24.76 SE) £192.2 (£33.33 SE) − £23.6 (− £106.11 to £58.92)
Incremental NMB (imputed, n = 439) £139.72 (£11.39 to £268.06)
≥ 2 years (n = 163)
 Baseline utility score 0.733 (0.151) 0.703 (0.200) 0.030 (− 0.024 to 0.085)
 2 weeks utility score 0.774 (0.138) 0.740 (0.189) 0.034 (− 0.017 to 0.085)
 6 weeks utility score 0.796 (0.147) 0.763 (0.172) 0.033 (− 0.017 to 0.082)
 12 weeks utility score 0.771 (0.204) 0.750 (0.189) 0.021 (− 0.040 to 0.082)
QALYs (imputed, n = 214) 0.175 (0.004 SE) 0.169 (0.004 SE) 0.005 (− 0.004 to 0.013)
Total NHS costs (imputed, n = 214) £124.02 (£21.63 SE) £144.37 (£31.65 SE) − £17.66 (− £92.59 to £57.27)
Incremental NMB (imputed, n = 214) £107.95 (− £79.84 to £295.74)
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(PHQ-9) at 6 weeks [16]. While there was evidence that 
sertraline reduced depressive symptoms by 12 weeks and 
reduced anxiety at 6 and 12 weeks, there was no evidence 
that symptom severity or duration affected response to either 
depressive or anxious symptoms [16]. Adverse events were 
rare (four adverse events for sertraline and three for placebo) 
[16]. In this paper, we have demonstrated that utility scores 
based on the EQ-5D-5L were marginally higher in the ser-
traline group at 6 and 12 weeks, although we cannot defini-
tively exclude no treatment effect. We used the newer five-
level version of the EQ-5D, which was developed to be more 
sensitive to changes in health status. However, it is possible 
that subgroups where sertraline was more cost-effective 
might have become more evident with longer follow-up or a 
more sensitive preference-based outcome measure.
Although the PANDA trial is, to our knowledge, the larg-
est trial of an antidepressant to explore differential cost-
effectiveness across prespecified subgroups, it was not 
designed to provide high statistical power on the economic 
outcome (NMB). Cost-effectiveness outcomes are often 
measured with less precision than clinical outcomes due to 
skewed cost distributions (through rare high-cost events) 
and a higher prevalence of missing data (as cost and QALY 
data are cumulative measures requiring complete data at 
every follow-up point). Approximately 40% of patients 
had at least one missing data point for resource use in the 
PANDA trial. This proportion is not unusual in primary 
care trials recruiting patients with depressive symptoms 
[36]. We assumed data were missing at random and used 
multiple imputation methods to minimise the risk of bias 
due to missing data. Nevertheless, missing data reduce the 
precision of our estimates and decrease the statistical power 
to identify differential cost-effectiveness across subgroups. 
We also analysed the two subgroup variables of severity 
and duration separately, but this neglects any correlation 
between them (e.g. in those for whom severity is related 
to duration).
We prespecified symptom severity and duration thresh-
olds in order to reduce the risk of a type 1 error, which 
could occur if multiple tests are used to compare subgroups 
defined by a large number of different severity and duration 
threshold values. However, the prespecified thresholds are 
essentially arbitrary values with “sharp” cut-off points, and 
it is possible that other threshold values might have better 
differentiated between subgroups where sertraline is more 
or less cost-effective. The PANDA trial only explored one 
of a large number of potential treatment options for primary 
care patients with depressive symptoms. The cost-effective-
ness of other options, such as cognitive behavioural ther-
apy, might also plausibly vary with symptom severity and 
duration. The expansion of access to psychological therapy 
increases the number of treatment options available and also 
the complexity of selecting the optimal treatment for patient 
subgroups [37].
4.3  Comparison with Other Studies
Guidelines for conducting economic evaluations alongside 
RCTs emphasise the value of subgroup analyses for decision 
makers and the importance of subgroup prespecification to 
minimise false-positive findings [38]. The National Institute 
of Health and Care Excellence (NICE) encourages estimates 
of the interaction between the treatment effect and prespeci-
fied, clinically plausible subgroups to identify patient char-
acteristics that increase or decrease the cost-effectiveness 
of the intervention [39]. However, NICE and other method 
guides [38] do not specify how cost-effectiveness subgroup 
analyses should be conducted or interpreted. Further meth-
odological guidance is needed in this area. The decision-
making approach, focussing on mean net benefits irrespec-
tive of statistical significance, could be applied to subgroup 
analyses [40], and would probably lead to coverage decisions 
based on a larger number of subgroups.
NICE note that not all patient subgroups (for example 
those defined by socioeconomic status) will provide an 
equitable basis for policy making, even if they are strongly 
associated with the intervention net benefit. The appropriate 
use of subgroups can increase population health by targeting 
spending at those patients where health gains are highest 
and/or opportunity costs are lowest [41]. In order to achieve 
this, subgroups need to be defined by characteristics that can 
be easily and objectively identified in clinical practice; in 
principle the severity and duration of depressive symptoms 
fit these criteria. Given the high cost and clinical uncertainty 
surrounding the appropriate prescribing of antidepressants 
in primary care, it is surprising that there is not a larger 
literature identifying subgroups where SSRIs are most (and 
least) cost-effective.
Fig. 3  Cost-effectiveness acceptability curves of sertraline versus pla-
cebo in patients with different levels of symptom duration (imputed)
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Previous work based on the THREAD RCT explored 
how the cost-effectiveness of an SSRI and supportive care 
versus supportive care alone in primary care patients with 
new episodes of mild to moderate depression might vary by 
patient subgroup [42, 43]. That work identified an associa-
tion between previous episodes of depression and the costs 
and QALY outcomes of treatment. Based on a comparison 
of CEACs by subgroup, they concluded that having no pre-
vious episode of depression was associated with a higher 
probability of the SSRI being cost-effective. Our findings, 
based on a larger sample size and a prespecified hypothesis, 
provide limited support for this finding. We found that while 
the incremental net benefit of sertraline was lower in patients 
with a longer duration of symptoms, the confidence intervals 
were wide and included zero (i.e. no interaction between 
duration and cost-effectiveness).
4.4  Implications for Practice and Research
It remains plausible that the cost-effectiveness of SSRIs is 
related to the duration of symptoms, but our data do not 
provide sufficient evidence that a threshold symptom dura-
tion of 2 years could be used to target prescribing. Individual 
patient data meta-analysis of SSRI RCTs (e.g. PANDA and 
THREAD) with economic evaluations could increase the 
power to detect meaningful subgroups. In practice, though, 
the lack of homogeneity between these trials (for example 
the use of a placebo control and the method used to measure 
QALYs) may limit the viability of this approach. This could 
improve with increased data sharing and the adoption of core 
cost and outcome sets in future trials.
Our findings demonstrate that sertraline is probably cost-
effective relative to placebo on average across the broad 
range of depressive symptom severities included in the 
PANDA trial. However, individual treatment decisions must 
assess the potential benefits and harms of sertraline. Caution 
and careful treatment monitoring is particularly required in 
young adults, where evidence suggests an increased risk of 
suicidal ideation with SSRI use [44, 45]. There was insuf-
ficient evidence that the use of sertraline was differentially 
cost-effective in any of the three severity subgroups explored 
in the PANDA economic analysis.
The relatively small differences in cost and outcomes 
observed between the sertraline and placebo groups will 
probably continue to make it difficult to identify subgroups 
where SSRI prescribing is markedly more cost-effective. 
Subgroup analyses based on economic evaluation may be 
more likely to be of value to policy makers in situations 
where the cost/efficacy/safety trade-offs are higher and 
where net benefit is more strongly associated with sub-
group characteristics. In these cases, statistical power will be 
improved, although large sample sizes will still be required 
to identify interactions with baseline characteristics.
5  Conclusions
There is currently insufficient evidence that the cost-effec-
tiveness of sertraline differs between subgroups defined 
by symptom severity and duration. Given this, it is likely 
that clinical judgement and patient preferences will con-
tinue to play the predominant role in the initiation of SSRI 
prescribing.
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